---
schema_version: "secwatch.filing_event.v1"
accession: "0001274737-22-000003"
form_type: "8-K"
ticker: "XGN"
cik: "0001274737"
company_name: "EXAGEN INC."
filed_at: "2022-01-10T23:59:59+00:00"
generated_at: "2026-06-27T19:14:12.751745+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Exagen provides AVISE RADR presentation; no material operational or financial news

## Summary
- Exagen released updated investor presentation highlighting its AVISE RADR test for rheumatoid arthritis drug response.
- Presentation dated January 10, 2022, focuses on the test's ability to predict drug response in RA patients.
- Company did not disclose any new financial results, guidance, or material events.

## SEC filing metadata
- accession: 0001274737-22-000003
- form_type: 8-K
- ticker: XGN
- cik: 0001274737
- company_name: EXAGEN INC.
- filed_at: 2022-01-10T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1274737/000127473722000003/0001274737-22-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1274737/000127473722000003/exdx-20220110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001274737-22-000003
- JSON: https://secwatch.observer/filing/0001274737-22-000003.json
- Plain text: https://secwatch.observer/filing/0001274737-22-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.